Clinical trials: Cardiovascular Risk Factors
Diabetes Mellitus
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease
The use of acarbose in impaired glucose tolerance (IGT) and type 2 diabetic subjects has been associated with a significant reduction of cardiovascular events.
- Trial name
- ABDOMEN (NCT01167231)
- Testing
- Acarbose (Glucobay, BAYG5421)
- Where
- Poland
- Volunteers
- 3,310 people
- Sponsor
- Bayer
Dyslipidemias, Cardiovascular Risk Factor
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican Population
Clinical Trial Phase III, experimental, simple blind, randomized with two treatment groups, multicentric, longitudinal, to evaluate the therapuetic efficacy to dislipydemias in mexican adult population.
- Trial name
- NCT03696940
- Testing
- L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg, Atorvastatin 10mg
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Laboratorios Grossman, S.A.
Obesity, Overweight
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
The purpose of this Phase 3b study is to assess the effects of combination therapy with naltrexone SR/bupropion SR (NB) used in conjunction with a comprehensive lifestyle intervention (CLI) and in a manner consistent with its…
- Trial name
- NCT01764386
- Testing
- NB, CLI, Usual Care
- Where
- 15 sites in United States
- Volunteers
- 242 people
- Sponsor
- Orexigen Therapeutics, Inc
Hypertension
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
This observational study is designed to evaluate the effects of Twynsta tablets with life style modifications on blood pressure, quality of life, and other risk factors in Korean patients with hypertension in a routine clinical…
- Trial name
- NCT01316419
- Testing
- Telmisartan, amlodipine
- Where
- 55 sites in South Korea
- Volunteers
- 2,089 people
- Sponsor
- Boehringer Ingelheim
Coronary Atherosclerosis
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered…
- Trial name
- NCT00124332
- Testing
- Rimonabant (SR141716)
- Where
- 9 sites in United States, Australia and 7 more
- Volunteers
- 839 people
- Sponsor
- Sanofi
Carotid Intima- Media Thickness
A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk Factors
This non-interventional, prospective, multi-centric, cross-sectional study is aimed to obtain the distribution of measurements of CIMT in Indian subjects and will involve approx. 30 investigative sites from all over the country.
- Trial name
- Score-India (NCT01551875)
- Where
- 24 sites in India
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Occupational Health
Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil
Introduction: As employees spent most part of their time at the worksite, it provides a venue to address multiple individual risk factors and promote health.
- Trial name
- NCT02055651
- Testing
- Examination and survey
- Where
- Brazil
- Volunteers
- 361 people, healthy volunteers welcome
- Sponsor
- Bayer
Cardiovascular Risk Factor
A Pilot Study to Investigate the Effect of Water-soluble Tomato Extract on TMAO
To determine the effect of 4 weeks daily consumption of Fruitflow on changes in plasma levels of fasting Trimethylamine N-oxide concentrations (TMAO)
- Trial name
- NCT04160481
- Testing
- FruitFlow
- Where
- Ireland
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Hypertension and Cardiovascular Risk Factors
Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors
To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the…
- Trial name
- EXCEL (NCT00579254)
- Testing
- CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)
- Volunteers
- 112 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cardiovascular Risk Factors, Hyperlipidemia
European Study of Cardiovascular Risk
The main objective of this study is to describe the management of patients with cardiovascular risk factors in primary prevention among different European countries.
- Conditions
- Cardiovascular Risk Factors, Hyperlipidemia, Hypertension, Diabetes
- Trial name
- EURIKA (NCT00882336)
- Where
- 775 sites in Austria, Belgium and 10 more
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca
Primary Hypercholesterolemia
A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)
This is a study to evaluate the lipid-altering efficacy, safety, and tolerability of ezetimibe when added to ongoing therapy with an 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin) in participants…
- Trial name
- NCT03882905
- Testing
- Ezetimibe, Simivastatin, Statin
- Volunteers
- 769 people
- Sponsor
- Organon and Co
Health, Subjective, Gastrointestinal Dysfunction
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
The LIFE-HOUSE research project is designed to evaluate the impact of a personalized lifestyle intervention program on functional capacity as an approach to quantitating health, and its relationship to well understood disease…
- Conditions
- Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases
- Trial name
- LIFE-HOUSE (NCT04005456)
- Testing
- Supplements and/or medical foods, Behavioral change support program, Food plan
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Cardiovascular Risk
Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk
This is a national, non interventional, prospective study performed in the general practice setting. The study has been designed : to assess the level of concordance between patients' cardiovascular risk perception and the…
- Trial name
- PERCEPTION (NCT01781416)
- Where
- France
- Volunteers
- 799 people
- Sponsor
- AstraZeneca
Cardiovascular Diseases
The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects
The purpose of this study is to determine the effect of theobromine on blood lipid parameters in healthy subjects. Secondary objectives are to determine the effect of cocoa and an interaction effect of cocoa and theobromine on…
- Trial name
- NCT01481389
- Testing
- Theobromine, Cocoa, Cocoa and theobromine
- Where
- France
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Risk Factor, Cardiovascular, Platelet Dysfunction Due to Drugs
Study of AggreGuide A-100 (ADP) Assay
Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet dysfunction caused by P2Y12 inhibitor antiplatelet therapy.
- Trial name
- NCT03111420
- Testing
- P2Y12 inhibitor, Platelet function test
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Aggredyne, Inc.
HYPERTENSION
Hypertension and Cardiovascular Risk Factors
A study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.
- Trial name
- NCT00171782
- Testing
- VALSARTAN+HYDROCHLOROTHIAZIDE
- Volunteers
- 76 people
- Sponsor
- Novartis
Hypercholesterolemia, Cardiovascular Risk Factor
Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk
This clinical study aims to assess the efficacy of 6 weeks 2.5g dose of TOTUM-070, a mix of 5 plant extracts, on lipid metabolism and cardiovascular health in individuals at increased cardio-metabolic risk.
- Conditions
- Hypercholesterolemia, Cardiovascular Risk Factor, Dyslipidemias, Atherosclerosis
- Trial name
- OLALIP (NCT05594979)
- Testing
- TOTUM-070
- Where
- France
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Valbiotis